Targeting the Vulnerabilities of Oncogene Activation

por Huang, Christina, Arbiser, Jack L.
Publicado 2023

MAVS is a double-edged sword

por Huang, Christina, Arbiser, Jack L.
Publicado 2023

Use of TYK2 inhibitor to relieve reactive granulomatous dermatitis due to myelodysplastic syndrome

por Huang, Christina, Berghoff, Adar, Arbiser, Jack L.
Publicado 2023

Successful treatment of palmoplantar psoriasis with chemical peeling and gentian violet

por Bubley, Jeffrey A., Alharthi, Maher, Arbiser, Jack L.
Publicado 2021

Mitochondrial Metabolism in Melanoma

por Huang, Christina, Radi, Rakan H., Arbiser, Jack L.
Publicado 2021

Targeting the duality of cancer

por Arbiser, Jack L., Bonner, Michael Y., Gilbert, Linda C.
Publicado 2017

Gentian violet induces wtp53 transactivation in cancer cells

por GARUFI, ALESSIA, D’ORAZI, VALERIO, ARBISER, JACK L., D’ORAZI, GABRIELLA
Publicado 2014

Inhibitors of cytoskeletal dynamics in malignant mesothelioma

por Reis, Katarina, Arbiser, Jack L., Hjerpe, Anders, Dobra, Katalin, Aspenström, Pontus
Publicado 2020

Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis

por Nagalingam, Arumugam, Arbiser, Jack L, Bonner, Michael Y, Saxena, Neeraj K, Sharma, Dipali
Publicado 2012

Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis

por Nagalingam, Arumugam, Arbiser, Jack L., Bonner, Michael Y., Saxena, Neeraj K., Sharma, Dipali
Publicado 2017

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo

por Bonner, Michael Y., Karlsson, Isabella, Rodolfo, Monica, Arnold, Rebecca S., Vergani, Elisabetta, Arbiser, Jack L.
Publicado 2016

Angiofibroma stimulation in a transgender person receiving gender-affirming testosterone

por Bubley, Jeffrey A., Yeung, Howa, Cole, Emily, Amin, Mariam, Parker, Douglas, Arbiser, Jack L.
Publicado 2020

Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo

por Radi, Rakan, Huang, Christina, Elsey, Justin, Jung, Yoon H., Corces, Victor G., Arbiser, Jack L.
Publicado 2022

Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer

por Avtanski, Dimiter B., Nagalingam, Arumugam, Bonner, Michael Y., Arbiser, Jack L., Saxena, Neeraj K., Sharma, Dipali
Publicado 2015

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol

por Zang, Hongjing, Qian, Guoqing, Arbiser, Jack, Owonikoko, Taofeek K., Ramalingam, Suresh S., Fan, Songqing, Sun, Shi‐Yong
Publicado 2020

Induction of remission in a patient with end-stage cutaneous T-cell lymphoma by concurrent use of radiation therapy, gentian violet, and mogamulizumab

por Westergaard, Sarah A., Lechowicz, Mary Jo, Harrington, Maggie, Elsey, Justin, Arbiser, Jack L., Khan, Mohammad K.
Publicado 2020

SIRT3 activation promotes enteric neurons survival and differentiation

por Balasubramaniam, Arun, Li, Ge, Ramanathan, Anita, Mwangi, Simon Musyoka, Hart, C. Michael, Arbiser, Jack L., Srinivasan, Shanthi
Publicado 2022

Peroxiredoxin 3 Is a Redox-Dependent Target of Thiostrepton in Malignant Mesothelioma Cells

por Newick, Kheng, Cunniff, Brian, Preston, Kelsey, Held, Paul, Arbiser, Jack, Pass, Harvey, Mossman, Brooke, Shukla, Arti, Heintz, Nicholas
Publicado 2012

Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner

por Avtanski, Dimiter B., Nagalingam, Arumugam, Kuppusamy, Panjamurthy, Bonner, Michael Y., Arbiser, Jack L., Saxena, Neeraj K., Sharma, Dipali
Publicado 2015

Honokiol, an activator of Sirtuin-3 (SIRT3) preserves mitochondria and protects the heart from doxorubicin-induced cardiomyopathy in mice

por Pillai, Vinodkumar B., Kanwal, Abhinav, Fang, Yong Hu, Sharp, Willard W., Samant, Sadhana, Arbiser, Jack, Gupta, Mahesh P.
Publicado 2017